| Vol. 11.45 – 27 November, 2020 |
| |
|
|
| In mouse models of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of polymer nanocarriers induced sufficient host T cells expressing tumor-specific chimeric antigen receptors or virus-specific T cell receptors to cause disease regression at levels similar to bolus infusions of ex vivo engineered lymphocytes. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators demonstrated that miR-199b-5p was significantly downregulated in metastatic prostate cancer (PCa) tissues and cells when compared with the normal prostate tissue, the localized disease, the weakly metastatic and androgen-dependent PCa cell, and the normal prostate epithelial cell. [British Journal of Cancer] |
|
|
|
| Scientists demonstrated that inhibiting the P2X4 receptor impaired the growth and mobility of prostate cancer cells but not apoptosis. In BALB/c immunocompromised nude mice inoculated with human PC3 cells subcutaneously, 5-BDBD showed anti-tumourigenic effects. [Cells] |
|
|
|
| Researchers demonstrated an approach to identify cancer-driver coregulators in cancer, and that PGC1α expression is clinically significant yet underexplored coregulator in aggressive early stage prostate cancer. [Scientific Reports] |
|
|
|
| Scientists indicated that upregulation of miR-211 has tumor-suppressive properties by inhibiting TGF-β pathway activation via inhibin-β A (INHBA) in prostate cancer stem cells. [Cancer Gene Therapy] |
|
|
|
| Overexpression of regucalcin in bone metastatic human prostate cancer PC-3 and DU-145 cells suppressed colony formation and cell growth in vitro. Overexpressed regucalcin enhanced the levels of p53, Rb, and p21, and decreased the levels of Ras, PI3 kinase, Akt, and mitogen-activated protein kinase, leading to suppression of cell growth. [Translational Oncology] |
|
|
|
| Isogenic androgen-responsive and castration-resistant human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts. [EJNMMI Research] |
|
|
|
| The authors demonstrated that elevating endogenous ceramide levels with administration of exogenous Ceramide Nanoliposomes was efficacious in androgen receptor (AR)-negative cell lines with limited efficacy in AR-positive cells. [iScience] |
|
|
|
| Investigators evaluated the potential effect of protein disulfide isomerase 4 on chemoresistance to docetaxel (DTX) in prostate cancer cells (DTX-resistant PC-3 cells and C4-2B cells) to investigate the underlying mechanisms. [Chemotherapy] |
|
|
|
|
| The authors expand on the clinical development of PARP inhibitors (PARPis) in metastatic castration-resistant prostate cancer, discuss potential biomarkers that may predict successful tumor control, and summarize present and future clinical research on PARPis in the metastatic disease landscape. [Cancers] |
|
|
|
|
| Blue Earth Diagnostics’ manufacturing partner, Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence. [Blue Earth Diagnostics] |
|
|
|
|
| April 11 – April 13, 2021 San Diego, California, United States |
|
|
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| The University of British Columbia (UBC) – Vancouver, British Columbia, Canada |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
|